Sign In
Buy NMRA
$1.74
-0.0100 (-0.571%)
At Close: Jun 03, 2026
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc. (NMRA) of a Class Action Lawsuit and an Upcoming Deadline
06:45pm, Monday, 24'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal s
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal s
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Neumora Therapeutics, Inc.(NASDAQ:NMRA) pursuant
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky
01:00pm, Monday, 24'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal s
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit First Filed by The Firm
12:32pm, Monday, 24'th Feb 2025
NEW YORK , Feb. 24, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the common stock of Neumora Therape
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action secu
Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class Action - NMRA
10:30am, Monday, 24'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal s
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Neumora Therapeutics, Inc.
10:00am, Monday, 24'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics,
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Neumora Therapeutics, Inc. (NMRA) Shareholders
07:25am, Monday, 24'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal s
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal s
SAN DIEGO, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal s
Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class Action - NMRA
02:47pm, Sunday, 23'rd Feb 2025
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal s
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Neumora Therapeutics, Inc.(NASDAQ:NMRA) pursuant
